Remove 2015 Remove Packaging Remove Pharmaceutical Companies
article thumbnail

Biopharma's costly blind spot: Exhausted minds, expensive mistakes

pharmaphorum

Skip to main content Thursday 7 August 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views (..)

article thumbnail

The Obesity Drug Development Summit has landed in Europe!

pharmaphorum

Skip to main content Friday 27 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Enabling the leaders of the future

pharmaphorum

iii] It’s no longer just about the company, compensation package and secondary benefits (e.g., Mark Larsen is vice president and head of human resources for Europe, Middle East and Africa (EMEA) at Janssen, the Pharmaceutical Companies of Johnson & Johnson. gym membership).

article thumbnail

Fixed-dose combination: Considerations for design, formulation, manufacturing and analysis

Pharmaceutical Technology

Pharmaceutical companies – and the FDA – are embracing FDCs. Between 2010 and the end of 2015, of the 655 New Drug Applications (NDAs) approved by the FDA, 63 were for FDCs. The potential to extend the patent life and market exclusivity of a company’s APIs is a potent financial incentive. The numbers tell the story.

article thumbnail

Digital investment promises to accelerate the use of wearable sensor data in clinical trials

pharmaphorum

Garabedian and his team plan to support VivoSense, not just with their funding package but with their industry network and connectivity. “We If pharmaceutical companies do not use this data, someone else will. This brings us to VivoSense. We believe that VivoSense is ‘the tip of the spear’ in this category.”.

article thumbnail

Building CO2-neutral, defossilised supply chains for chemicals

European Pharmaceutical Review

All traditional small molecule pharmaceuticals include carbon building blocks – by definition, organic materials – which are then transformed via modern synthetic chemistry to assemble the complex and highly variable skeletons that the final target structures demand. In 2015 he joined the Process Chemistry & Catalysis group at F.

article thumbnail

Are microtaggants the key to making medicines smarter?

pharmaphorum

Pharmaceutical companies are accountable for ensuring that their medicine is safe when it comes into the hands of patients. Many countries have introduced serialisation legislation which requires product identifiers to be affixed to each package to provide traceability throughout the distribution supply chain.